CUPRIC SULFATE | N019350 | ABRAXIS PHARMACEUTICAL PRODUCTS
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Arent Fox LLP FDA-2021-P-1188 · 5 docket documents On November 2, 2021, Arent Fox LLP filed a citizen petition under 21 CFR 10.25(a) and 10.30 requesting that the FDA Commissioner determine that Cupric Sulfate Injection, 0.4 mg Copper/mL, approved under NDA 019350 and held by Abraxis Pharmaceutical Products, was not withdrawn from marketing for safe | 505(q) | 2021-11-03 | Granted | Arent Fox LLP |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.